Article
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
International journal of cancer - 1 May 2011
Tie Jeanne, Gibbs Peter, Lipton Lara, Christie Michael, Jorissen Robert N, Burgess Antony W, Croxford Matthew, Jones Ian, Langland Rachel, Kosmider Suzanne, McKay Daniel, Bollag Gideon, Nolop Keith, Sieber Oliver M, Desai Jayesh
Abstract excerpt
BRAF(V600E) mutations are found in 10% of colorectal cancers (CRCs). The low frequency of this mutation therefore makes it a challenging target for drug development, unless subsets of patients with higher rates of BRAF(V600E) can be defined. Knowledge of the concordance between primary-metastasis pairs and the impact of BRAF(V600E) on outcome would also assist in optimal drug development. We selected primary CRCs...
Topics
- Age Factors
- Aged
- Antineoplastic Agents
- Colorectal Neoplasms
- Drug Delivery Systems
- Drug Resistance, Neoplasm
- Female
- Humans
- Kaplan-Meier Estimate